Accelerated Approval Is US FDA Panel’s Preferred Path For Biogen/Ionis’s Tofersen In ALS

 
• By Sue Sutter
Edge of cliff
Most FDA adcomm members were unwilling to make the leap to regular approval for tofersen. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers